- Enhancing kidney care through innovative approaches by
data-driven insights and real-world evidence
- Company-wide experts highlight robust anonymized dialysis
database
- CONVINCE study and the remarkable decrease of 23% in mortality
rates for patients treated with high-volume hemodiafiltration
will be presented
BAD HOMBURG, Germany, May 21, 2024
/PRNewswire/ -- Fresenius Medical Care (FME), the world's
leading provider of products and services for individuals with
renal diseases, today announced the presentation of nearly 40
company-affiliated research abstracts at the 61st
European Renal Association (ERA) Congress, taking place
May 23-26, 2024, in Stockholm, Sweden and virtually.
"Our mission to improve the lives of people living with kidney
disease requires working continually to enhance the standard of
kidney disease care, and research plays an important role in that
advancement," said Dr. Frank Maddux,
Global Chief Medical Officer and Member of the Management Board for
Fresenius Medical Care. "We're proud to share some of our company's
latest research, delving into critical areas such as
hemodiafiltration and hemodialysis therapies, using machine
learning and artificial intelligence to drive insights, and
advances in kidney care worldwide."
A link to all Fresenius Medical Care-affiliated presentations
can be found here: 61st ERA Congress | Fresenius Medical Care.
Highlights of this year's posters for the congress include:
- Comparison of Baseline Patient Characteristics of the CONVINCE
Randomized Controlled Trial with Existing Trial and Registry
Populations (May 24, Poster
available from 16:45 CEST) A key to
generalize the results of randomized trials in everyday clinical
practice is how similar the study population is with the one we
treat in real life. Comparison of key characteristics of the
CONVINCE trial population with that of other randomized controlled
trials and important dialysis registries from Europe, USA,
and Australasia showed no major differences for age, sex, diabetes,
cardiovascular disease, and prevalence of arteriovenous
fistula.
- Validation of Artificial Intelligence Algorithm
Classifying Arteriovenous Access Aneurysms in Hemodialysis: a
Blinded Multicenter Prospective Study (May 23, Poster available from 00:11 CEST) Our AI-powered application
demonstrated actionable accuracy in classifying arteriovenous
access aneurysms within a demographically diverse HD population,
enabling timely detection and interventions to prevent severe and
potentially life-threatening outcomes such as sudden rupture.
- Use of Machine Learning Directed Interventions to Reduce Fluid
Related Hospital Admissions in Hemodialysis
Patients (May 24, Poster
available from 15:15 CEST)
The assessment of our machine learning model aimed at predicting
hospitalization risk among hemodialysis patients due to
fluid overload revealed encouraging findings. Notably, patients
identified as high risk by the model who subsequently received
intervention from nurses experienced substantial decrease in both
fluid and all cause hospital admissions between baseline and
follow-up period compared to those who did not receive any
intervention.
- Application of ChatGPT to Support Nutritional
Recommendations for Dialysis Patients (May 24, Poster available from 17:40 CEST)
We explored the use of a Large Language Model (LLM),
specifically, ChatGPT (GPT-4 model,
openai.com), to support nutritional advice given to dialysis
patients in a diverse population. The renal dietitian rated the
recipes and cooking instructions as moderately satisfactory, but
the nutritional analysis questionable. ChatGPT
underestimated calories by 36%, protein by 28%, and fat,
phosphorus, potassium, and sodium by around 50%. Our findings
underscore the importance of a critical approach and the need to
assess qualitatively and quantitatively the output created
by LLMs.
- Quantitative Analysis of Dialytic Protein Loss with Medium
Cut-Off and High-Flux Membranes (May
24, Poster available from 9 :10 CEST): We built an ex
vivo system to test two dialyzers concurrently and implemented a
robust proteomics workflow for a direct comparison of protein loss
in the ultrafiltrate. Our data indicates, comprehensively and
consistently, a greater extent of protein loss with Medium Cut-off
membrane compared to High-Flux membranes, including the loss of
salutary proteins.
- Dialysis Modality Patterns Across Six Continents in Apollo Dial
DB (May 25, Poster available
from 12:35 CEST) : Capturing
data from over 40 countries, Apollo DB is an anonymized dialysis
database that combines and harmonizes data from a global provider
for research and quality improvement activities.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products
and services for individuals with renal diseases of which around
4.1 million patients worldwide regularly undergo dialysis
treatment. Through its network of 3,862 dialysis clinics, Fresenius
Medical Care provides dialysis treatments for approx. 325,000
patients around the globe. Fresenius Medical Care is also the
leading provider of dialysis products such as dialysis machines or
dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock
Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Company's website
at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject
to various risks and uncertainties. Actual results could differ
materially from those described in these forward-looking statements
due to various factors, including, but not limited to, changes in
business, economic and competitive conditions, legal changes,
regulatory approvals, impacts related to the COVID-19 pandemic
results of clinical studies, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties
are detailed in Fresenius Medical Care's reports filed with the
U.S. Securities and Exchange Commission. Fresenius Medical Care
does not undertake any responsibility to update the forward-looking
statements in this release.
Media contact
Christine Peters
T
+49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Kirsten Stratton
T +1 781 929 8096
kirsten.stratton@freseniusmedicalcare.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-showcases-leadership-and-innovation-in-kidney-care-disease-at-61st-european-renal-association-era-congress-2024-302151538.html
SOURCE Fresenius Medical Care Holdings, Inc.